Bluejay Diagnostics Inc.
BJDX
Bluejay Diagnostics, Inc. ( Bluejay ) is a medical diagnostics company focused on improving patient outcomes in critical care settings, with a focus on sepsis. We are working on developing rapid, near-patient tests using whole blood on our Symphony technology platform ( Symphony ), which consists of an analyzer and single-use protein detection cartridges.
Valuation & Multiples
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$8M
▲ +11.3% YoY
Op. Margin
–
ROIC
-90.14%
▲ +31.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$7M
▲ +23.4% YoY
Op. Cash Flow (TTM)
-$7M
▲ +22.6% YoY
Net Debt
-$7M
Net Cash Position
Cash & Equiv.
$7M
Continue Research
Peers
Surgical & Medical Instruments & Apparatus · Pick stocks to compare with BJDX
Bluejay Diagnostics (BJDX) in three numbers
Questions about Bluejay Diagnostics
Is Bluejay Diagnostics (BJDX) overvalued?
Bluejay Diagnostics trades at 0.09 times earnings. Intrinsiqq's fair value calculator has no opening value for BJDX, so weigh those multiples against the company's own history and the peers above. See how to tell if a stock is overvalued.
Is Bluejay Diagnostics a high-quality business?
Bluejay Diagnostics scores 20 out of 100 on Intrinsiqq's quality score, which makes it a lower-quality business on these measures. The score blends 4 checks computed from SEC filings. Its best check is net debt at -$7M, and its weakest is return on capital at -90.1%. The Quality tab shows every check against its target.
Does Bluejay Diagnostics (BJDX) pay a dividend?
No. Bluejay Diagnostics (BJDX) does not pay a dividend, and no dividend payment appears anywhere in the filing history we hold. Nor has its share count fallen meaningfully over the last twelve months, so cash is kept in the business. The Dividends tab shows its cash returns.
Source: 10-Q filed 3 Nov 2026 (period ending 30 Sept 2026), SEC. Price: last close 20 Nov 2026. How this is calculated. Sector medians are approximate S&P 500 benchmarks and update periodically. Analysis, not investment advice.
Spot a number that looks wrong? Check it in BJDX's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BJDX
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.